MFG
APRE icon

Magnus Financial Group’s Aprea Therapeutics APRE Stock Holding History

Magnus Financial Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-743
Closed -$28K – 278
2022
Q1 		$28K Sell
743
-956
-56% -$39.2K ﹤0.01% 289
2021
Q4 		$98K Buy
+1,699
New +$150K 0.02% 256

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Magnus Financial Group's APRE Position: Q2 2022 in Review

Magnus Financial Group sold out of Aprea Therapeutics (APRE) in Q2 2022, closing a stake of 743 shares — an estimated $28K sold.

Magnus Financial Group first reported a position in APRE in Q4 2021 and held it in 2 quarters. The position peaked at $98K in Q4 2021. 33 funds tracked by Wall St. Rank hold APRE as of Q2 2022.

  • Magnus Financial Group reported no remaining Aprea Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Magnus Financial Group sold 743 Aprea Therapeutics shares in Q2 2022, an estimated $28K.
  • Magnus Financial Group first reported a position in Aprea Therapeutics in Q4 2021 and held it in 2 quarters.
  • Magnus Financial Group's Aprea Therapeutics position peaked at $98K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2022.

Based on Magnus Financial Group's 13F filing for Q2 2022, filed 11 Aug 2022.